APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid-Induced Constipation

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Selected research

Market Analysis & Forecast

Global Opioid-Induced Constipation Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchOpioid-Induced Constipation Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid-Induced Constipation Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Opioid-Induced Constipation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid-Induced Constipation Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid-Induced Constipation Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

Read the full market overview

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

This report presents an overview of global market for Opioid-Induced Constipation, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Opioid-Induced Constipation, also provides the sales of main regions and countries. Of the upcoming market potential for Opioid-Induced Constipation, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Opioid-Induced Constipation sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Opioid-Induced Constipation market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Opioid-Induced Constipation sales, projected growth trends, production technology, application and end-user industry.

Opioid-Induced Constipation Segment by Company

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

Opioid-Induced Constipation Segment by Type

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Opioid-Induced Constipation Segment by Application

Hospital

Pharmacy

Other

Opioid-Induced Constipation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid-Induced Constipation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid-Induced Constipation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid-Induced Constipation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Opioid-Induced Constipation in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Opioid-Induced Constipation sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Methylnaltrexone Bromide Major Manufacturers Table 3. Lubiprostone Major Manufacturers Table 4. Naloxegol Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Opioid-Induced Constipation Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Pharmacy Major Manufacturers Table 9. Other Major Manufacturers Table 10. Opioid-Induced Constipation Industry Trends Table 11. Opioid-Induced Constipation Industry Drivers Table 12. Opioid-Induced Constipation Industry Opportunities and Challenges Table 13. Opioid-Induced Constipation Industry Restraints Table 14. Global Opioid-Induced Constipation Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Opioid-Induced Constipation Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Opioid-Induced Constipation Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Opioid-Induced Constipation Revenue Market Share by Region (2021-2026) Table 18. Global Opioid-Induced Constipation Revenue Market Share by Region (2027-2032) Table 19. Global Opioid-Induced Constipation Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Opioid-Induced Constipation Sales by Region (2021-2026) & (K Units) Table 21. Global Opioid-Induced Constipation Sales by Region (2027-2032) & (K Units) Table 22. Global Opioid-Induced Constipation Sales Market Share by Region (2021-2026) Table 23. Global Opioid-Induced Constipation Sales Market Share by Region (2027-2032) Table 24. Global Opioid-Induced Constipation Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Opioid-Induced Constipation Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2021-2026) Table 28. Global Opioid-Induced Constipation Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 29. Global Opioid-Induced Constipation Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Opioid-Induced Constipation Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Opioid-Induced Constipation Manufacturers, Product Type & Application Table 32. Global Opioid-Induced Constipation Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Opioid-Induced Constipation by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Opioid-Induced Constipation Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Opioid-Induced Constipation Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Opioid-Induced Constipation Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Opioid-Induced Constipation Revenue Market Share by Type (2021-2026) Table 39. Global Opioid-Induced Constipation Revenue Market Share by Type (2027-2032) Table 40. Global Opioid-Induced Constipation Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 42. Global Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 43. Global Opioid-Induced Constipation Sales Market Share by Type (2021-2026) Table 44. Global Opioid-Induced Constipation Sales Market Share by Type (2027-2032) Table 45. Global Opioid-Induced Constipation Price by Type (2021-2026) & (USD/Unit) Table 46. Global Opioid-Induced Constipation Price by Type (2027-2032) & (USD/Unit) Table 47. Global Opioid-Induced Constipation Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Opioid-Induced Constipation Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Opioid-Induced Constipation Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Opioid-Induced Constipation Revenue Market Share by Application (2021-2026) Table 51. Global Opioid-Induced Constipation Revenue Market Share by Application (2027-2032) Table 52. Global Opioid-Induced Constipation Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 54. Global Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 55. Global Opioid-Induced Constipation Sales Market Share by Application (2021-2026) Table 56. Global Opioid-Induced Constipation Sales Market Share by Application (2027-2032) Table 57. Global Opioid-Induced Constipation Price by Application (2021-2026) & (USD/Unit) Table 58. Global Opioid-Induced Constipation Price by Application (2027-2032) & (USD/Unit) Table 59. Takeda Pharmaceuticals Company Information Table 60. Takeda Pharmaceuticals Business Overview Table 61. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 62. Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 63. Takeda Pharmaceuticals Recent Development Table 64. Bayer Company Information Table 65. Bayer Business Overview Table 66. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 67. Bayer Opioid-Induced Constipation Product Portfolio Table 68. Bayer Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 72. Sanofi Opioid-Induced Constipation Product Portfolio Table 73. Sanofi Recent Development Table 74. Mallinckrodt Company Information Table 75. Mallinckrodt Business Overview Table 76. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 77. Mallinckrodt Opioid-Induced Constipation Product Portfolio Table 78. Mallinckrodt Recent Development Table 79. Salix (Bausch Health) Company Information Table 80. Salix (Bausch Health) Business Overview Table 81. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 82. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio Table 83. Salix (Bausch Health) Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 87. AstraZeneca Opioid-Induced Constipation Product Portfolio Table 88. AstraZeneca Recent Development Table 89. Progenics Pharmaceuticals Company Information Table 90. Progenics Pharmaceuticals Business Overview Table 91. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 93. Progenics Pharmaceuticals Recent Development Table 94. Purdue Pharm Company Information Table 95. Purdue Pharm Business Overview Table 96. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Purdue Pharm Opioid-Induced Constipation Product Portfolio Table 98. Purdue Pharm Recent Development Table 99. Nektar Therapeutics Company Information Table 100. Nektar Therapeutics Business Overview Table 101. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Nektar Therapeutics Opioid-Induced Constipation Product Portfolio Table 103. Nektar Therapeutics Recent Development Table 104. Daiichi Sankyo Company Information Table 105. Daiichi Sankyo Business Overview Table 106. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. Daiichi Sankyo Opioid-Induced Constipation Product Portfolio Table 108. Daiichi Sankyo Recent Development Table 109. Prestige Company Information Table 110. Prestige Business Overview Table 111. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 112. Prestige Opioid-Induced Constipation Product Portfolio Table 113. Prestige Recent Development Table 114. GSK Company Information Table 115. GSK Business Overview Table 116. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 117. GSK Opioid-Induced Constipation Product Portfolio Table 118. GSK Recent Development Table 119. Shionogi Company Information Table 120. Shionogi Business Overview Table 121. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 122. Shionogi Opioid-Induced Constipation Product Portfolio Table 123. Shionogi Recent Development Table 124. North America Opioid-Induced Constipation Revenue by Type (2021-2026) & (US$ Million) Table 125. North America Opioid-Induced Constipation Revenue by Type (2027-2032) & (US$ Million) Table 126. North America Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 127. North America Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 128. North America Opioid-Induced Constipation Sales Price by Type (2021-2026) & (USD/Unit) Table 129. North America Opioid-Induced Constipation Sales Price by Type (2027-2032) & (USD/Unit) Table 130. North America Opioid-Induced Constipation Revenue by Application (2021-2026) & (US$ Million) Table 131. North America Opioid-Induced Constipation Revenue by Application (2027-2032) & (US$ Million) Table 132. North America Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 133. North America Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 134. North America Opioid-Induced Constipation Sales Price by Application (2021-2026) & (USD/Unit) Table 135. North America Opioid-Induced Constipation Sales Price by Application (2027-2032) & (USD/Unit) Table 136. North America Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Opioid-Induced Constipation Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. North America Opioid-Induced Constipation Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. North America Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 140. North America Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 141. North America Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 142. North America Opioid-Induced Constipation Sales Price by Country (2021-2026) & (USD/Unit) Table 143. North America Opioid-Induced Constipation Sales Price by Country (2027-2032) & (USD/Unit) Table 144. United States Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 145. Canada Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 146. Mexico Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 147. Europe Opioid-Induced Constipation Revenue by Type (2021-2026) & (US$ Million) Table 148. Europe Opioid-Induced Constipation Revenue by Type (2027-2032) & (US$ Million) Table 149. Europe Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 150. Europe Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 151. Europe Opioid-Induced Constipation Sales Price by Type (2021-2026) & (USD/Unit) Table 152. Europe Opioid-Induced Constipation Sales Price by Type (2027-2032) & (USD/Unit) Table 153. Europe Opioid-Induced Constipation Revenue by Application (2021-2026) & (US$ Million) Table 154. Europe Opioid-Induced Constipation Revenue by Application (2027-2032) & (US$ Million) Table 155. Europe Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 156. Europe Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 157. Europe Opioid-Induced Constipation Sales Price by Application (2021-2026) & (USD/Unit) Table 158. Europe Opioid-Induced Constipation Sales Price by Application (2027-2032) & (USD/Unit) Table 159. Europe Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Europe Opioid-Induced Constipation Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. Europe Opioid-Induced Constipation Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. Europe Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 163. Europe Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 164. Europe Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 165. Europe Opioid-Induced Constipation Sales Price by Country (2021-2026) & (USD/Unit) Table 166. Europe Opioid-Induced Constipation Sales Price by Country (2027-2032) & (USD/Unit) Table 167. Germany Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 168. France Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 169. U.K. Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 170. Italy Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 171. Russia Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 172. Spain Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 173. Netherlands Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 174. Switzerland Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 175. Sweden Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 176. Poland Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 177. China Opioid-Induced Constipation Revenue by Type (2021-2026) & (US$ Million) Table 178. China Opioid-Induced Constipation Revenue by Type (2027-2032) & (US$ Million) Table 179. China Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 180. China Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 181. China Opioid-Induced Constipation Sales Price by Type (2021-2026) & (USD/Unit) Table 182. China Opioid-Induced Constipation Sales Price by Type (2027-2032) & (USD/Unit) Table 183. China Opioid-Induced Constipation Revenue by Application (2021-2026) & (US$ Million) Table 184. China Opioid-Induced Constipation Revenue by Application (2027-2032) & (US$ Million) Table 185. China Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 186. China Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 187. China Opioid-Induced Constipation Sales Price by Application (2021-2026) & (USD/Unit) Table 188. China Opioid-Induced Constipation Sales Price by Application (2027-2032) & (USD/Unit) Table 189. Asia Opioid-Induced Constipation Revenue by Type (2021-2026) & (US$ Million) Table 190. Asia Opioid-Induced Constipation Revenue by Type (2027-2032) & (US$ Million) Table 191. Asia Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 192. Asia Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 193. Asia Opioid-Induced Constipation Sales Price by Type (2021-2026) & (USD/Unit) Table 194. Asia Opioid-Induced Constipation Sales Price by Type (2027-2032) & (USD/Unit) Table 195. Asia Opioid-Induced Constipation Revenue by Application (2021-2026) & (US$ Million) Table 196. Asia Opioid-Induced Constipation Revenue by Application (2027-2032) & (US$ Million) Table 197. Asia Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 198. Asia Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 199. Asia Opioid-Induced Constipation Sales Price by Application (2021-2026) & (USD/Unit) Table 200. Asia Opioid-Induced Constipation Sales Price by Application (2027-2032) & (USD/Unit) Table 201. Asia Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. Asia Opioid-Induced Constipation Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. Asia Opioid-Induced Constipation Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. Asia Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 205. Asia Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 206. Asia Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 207. Asia Opioid-Induced Constipation Sales Price by Country (2021-2026) & (USD/Unit) Table 208. Asia Opioid-Induced Constipation Sales Price by Country (2027-2032) & (USD/Unit) Table 209. Japan Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 210. South Korea Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 211. India Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 212. Australia Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 213. Taiwan Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 214. Southeast Asia Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 215. SAMEA Opioid-Induced Constipation Revenue by Type (2021-2026) & (US$ Million) Table 216. SAMEA Opioid-Induced Constipation Revenue by Type (2027-2032) & (US$ Million) Table 217. SAMEA Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 218. SAMEA Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 219. SAMEA Opioid-Induced Constipation Sales Price by Type (2021-2026) & (USD/Unit) Table 220. SAMEA Opioid-Induced Constipation Sales Price by Type (2027-2032) & (USD/Unit) Table 221. SAMEA Opioid-Induced Constipation Revenue by Application (2021-2026) & (US$ Million) Table 222. SAMEA Opioid-Induced Constipation Revenue by Application (2027-2032) & (US$ Million) Table 223. SAMEA Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 224. SAMEA Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 225. SAMEA Opioid-Induced Constipation Sales Price by Application (2021-2026) & (USD/Unit) Table 226. SAMEA Opioid-Induced Constipation Sales Price by Application (2027-2032) & (USD/Unit) Table 227. SAMEA Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 228. SAMEA Opioid-Induced Constipation Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 229. SAMEA Opioid-Induced Constipation Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 230. SAMEA Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 231. SAMEA Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 232. SAMEA Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 233. SAMEA Opioid-Induced Constipation Sales Price by Country (2021-2026) & (USD/Unit) Table 234. SAMEA Opioid-Induced Constipation Sales Price by Country (2027-2032) & (USD/Unit) Table 235. Brazil Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 236. Argentina Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 237. Chile Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 238. Colombia Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 239. Peru Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 240. Saudi Arabia Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 241. Israel Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 242. UAE Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 243. Turkey Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 244. Iran Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 245. Egypt Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Table 246. Key Raw Materials Table 247. Raw Materials Key Suppliers Table 248. Opioid-Induced Constipation Distributors List Table 249. Opioid-Induced Constipation Customers List Table 250. Research Programs/Design for This Report Table 251. Authors List of This Report Table 252. Secondary Sources Table 253. Primary Sources List of Figures Figure 1. Opioid-Induced Constipation Image Figure 2. Global Opioid-Induced Constipation Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid-Induced Constipation Market Size Share 2021 VS 2025 VS 2032 Figure 4. Methylnaltrexone Bromide Image Figure 5. Lubiprostone Image Figure 6. Naloxegol Image Figure 7. Others Image Figure 8. Global Opioid-Induced Constipation Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Opioid-Induced Constipation Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Pharmacy Image Figure 12. Other Image Figure 13. Global Opioid-Induced Constipation Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Figure 15. Global Opioid-Induced Constipation Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Opioid-Induced Constipation Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Opioid-Induced Constipation Revenue Market Share by Region (2021-2032) Figure 18. Global Opioid-Induced Constipation Sales (2021-2032) & (K Units) Figure 19. Global Opioid-Induced Constipation Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Opioid-Induced Constipation Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Opioid-Induced Constipation Sales YoY (2021-2032) & (K Units) Figure 22. Europe Opioid-Induced Constipation Sales YoY (2021-2032) & (K Units) Figure 23. China Opioid-Induced Constipation Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Opioid-Induced Constipation Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Opioid-Induced Constipation Sales YoY (2021-2032) & (K Units) Figure 26. Global Opioid-Induced Constipation Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Opioid-Induced Constipation Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Opioid-Induced Constipation Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Opioid-Induced Constipation Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Opioid-Induced Constipation Revenue Market Share by Type (2021-2032) Figure 32. Global Opioid-Induced Constipation Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Opioid-Induced Constipation Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Opioid-Induced Constipation Sales Market Share by Type (2021-2032) Figure 35. Global Opioid-Induced Constipation Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Opioid-Induced Constipation Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Opioid-Induced Constipation Revenue Market Share by Application (2021-2032) Figure 38. Global Opioid-Induced Constipation Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Opioid-Induced Constipation Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Opioid-Induced Constipation Sales Market Share by Application (2021-2032) Figure 41. North America Opioid-Induced Constipation Revenue Share by Type (2021-2032) Figure 42. North America Opioid-Induced Constipation Sales Share by Type (2021-2032) Figure 43. North America Opioid-Induced Constipation Revenue Share by Application (2021-2032) Figure 44. North America Opioid-Induced Constipation Sales Share by Application (2021-2032) Figure 45. North America Opioid-Induced Constipation Revenue Share by Country (2021-2032) Figure 46. North America Opioid-Induced Constipation Sales Share by Country (2021-2032) Figure 47. Europe Opioid-Induced Constipation Revenue Share by Type (2021-2032) Figure 48. Europe Opioid-Induced Constipation Sales Share by Type (2021-2032) Figure 49. Europe Opioid-Induced Constipation Revenue Share by Application (2021-2032) Figure 50. Europe Opioid-Induced Constipation Sales Share by Application (2021-2032) Figure 51. Europe Opioid-Induced Constipation Revenue Share by Country (2021-2032) Figure 52. Europe Opioid-Induced Constipation Sales Share by Country (2021-2032) Figure 53. China Opioid-Induced Constipation Revenue Share by Type (2021-2032) Figure 54. China Opioid-Induced Constipation Sales Share by Type (2021-2032) Figure 55. China Opioid-Induced Constipation Revenue Share by Application (2021-2032) Figure 56. China Opioid-Induced Constipation Sales Share by Application (2021-2032) Figure 57. Asia Opioid-Induced Constipation Revenue Share by Type (2021-2032) Figure 58. Asia Opioid-Induced Constipation Sales Share by Type (2021-2032) Figure 59. Asia Opioid-Induced Constipation Revenue Share by Application (2021-2032) Figure 60. Asia Opioid-Induced Constipation Sales Share by Application (2021-2032) Figure 61. Asia Opioid-Induced Constipation Revenue Share by Country (2021-2032) Figure 62. Asia Opioid-Induced Constipation Sales Share by Country (2021-2032) Figure 63. SAMEA Opioid-Induced Constipation Revenue Share by Type (2021-2032) Figure 64. SAMEA Opioid-Induced Constipation Sales Share by Type (2021-2032) Figure 65. SAMEA Opioid-Induced Constipation Revenue Share by Application (2021-2032) Figure 66. SAMEA Opioid-Induced Constipation Sales Share by Application (2021-2032) Figure 67. SAMEA Opioid-Induced Constipation Revenue Share by Country (2021-2032) Figure 68. SAMEA Opioid-Induced Constipation Sales Share by Country (2021-2032) Figure 69. Opioid-Induced Constipation Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Opioid-Induced Constipation Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Others
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Bayer
  • Sanofi
  • Mallinckrodt
  • Salix (Bausch Health)
  • AstraZeneca
  • Progenics Pharmaceuticals
  • Purdue Pharm
  • Nektar Therapeutics
  • Daiichi Sankyo
  • Prestige
  • GSK
  • Shionogi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Opioid-Induced Constipation Market by Type
  3. 1.2.1 Global Opioid-Induced Constipation Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Methylnaltrexone Bromide
  5. 1.2.3 Lubiprostone
  6. 1.2.4 Naloxegol
  7. 1.2.5 Others
  8. 1.3 Opioid-Induced Constipation Market by Application
  9. 1.3.1 Global Opioid-Induced Constipation Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Opioid-Induced Constipation Market Dynamics
  1. 2.1 Opioid-Induced Constipation Industry Trends
  2. 2.2 Opioid-Induced Constipation Industry Drivers
  3. 2.3 Opioid-Induced Constipation Industry Opportunities and Challenges
  4. 2.4 Opioid-Induced Constipation Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Opioid-Induced Constipation Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Opioid-Induced Constipation Revenue by Region
  3. 3.2.1 Global Opioid-Induced Constipation Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Opioid-Induced Constipation Revenue by Region (2021-2026)
  5. 3.2.3 Global Opioid-Induced Constipation Revenue by Region (2027-2032)
  6. 3.2.4 Global Opioid-Induced Constipation Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Opioid-Induced Constipation Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Opioid-Induced Constipation Sales by Region
  9. 3.4.1 Global Opioid-Induced Constipation Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Opioid-Induced Constipation Sales by Region (2021-2026)
  11. 3.4.3 Global Opioid-Induced Constipation Sales by Region (2027-2032)
  12. 3.4.4 Global Opioid-Induced Constipation Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Opioid-Induced Constipation Revenue by Manufacturers
  2. 4.1.1 Global Opioid-Induced Constipation Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Opioid-Induced Constipation Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Opioid-Induced Constipation Sales by Manufacturers
  6. 4.2.1 Global Opioid-Induced Constipation Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Opioid-Induced Constipation Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Opioid-Induced Constipation Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Opioid-Induced Constipation Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Opioid-Induced Constipation Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Opioid-Induced Constipation Manufacturers, Product Type & Application
  13. 4.7 Global Opioid-Induced Constipation Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Opioid-Induced Constipation Market CR5 and HHI
  16. 4.8.2 2025 Opioid-Induced Constipation Tier 1, Tier 2, and Tier 3
5 Opioid-Induced Constipation Market by Type
  1. 5.1 Global Opioid-Induced Constipation Revenue by Type
  2. 5.1.1 Global Opioid-Induced Constipation Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Opioid-Induced Constipation Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Opioid-Induced Constipation Sales by Type
  6. 5.2.1 Global Opioid-Induced Constipation Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid-Induced Constipation Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Opioid-Induced Constipation Sales Market Share by Type (2021-2032)
  9. 5.3 Global Opioid-Induced Constipation Price by Type
6 Opioid-Induced Constipation Market by Application
  1. 6.1 Global Opioid-Induced Constipation Revenue by Application
  2. 6.1.1 Global Opioid-Induced Constipation Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Opioid-Induced Constipation Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Opioid-Induced Constipation Sales by Application
  6. 6.2.1 Global Opioid-Induced Constipation Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Opioid-Induced Constipation Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Opioid-Induced Constipation Sales Market Share by Application (2021-2032)
  9. 6.3 Global Opioid-Induced Constipation Price by Application
7 Company Profiles
  1. 7.1 Takeda Pharmaceuticals
  2. 7.1.1 Takeda Pharmaceuticals Company Information
  3. 7.1.2 Takeda Pharmaceuticals Business Overview
  4. 7.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  6. 7.1.5 Takeda Pharmaceuticals Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Opioid-Induced Constipation Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Mallinckrodt
  20. 7.4.1 Mallinckrodt Company Information
  21. 7.4.2 Mallinckrodt Business Overview
  22. 7.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
  24. 7.4.5 Mallinckrodt Recent Developments
  25. 7.5 Salix (Bausch Health)
  26. 7.5.1 Salix (Bausch Health) Company Information
  27. 7.5.2 Salix (Bausch Health) Business Overview
  28. 7.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
  30. 7.5.5 Salix (Bausch Health) Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Progenics Pharmaceuticals
  38. 7.7.1 Progenics Pharmaceuticals Company Information
  39. 7.7.2 Progenics Pharmaceuticals Business Overview
  40. 7.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  42. 7.7.5 Progenics Pharmaceuticals Recent Developments
  43. 7.8 Purdue Pharm
  44. 7.8.1 Purdue Pharm Company Information
  45. 7.8.2 Purdue Pharm Business Overview
  46. 7.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
  48. 7.8.5 Purdue Pharm Recent Developments
  49. 7.9 Nektar Therapeutics
  50. 7.9.1 Nektar Therapeutics Company Information
  51. 7.9.2 Nektar Therapeutics Business Overview
  52. 7.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
  54. 7.9.5 Nektar Therapeutics Recent Developments
  55. 7.10 Daiichi Sankyo
  56. 7.10.1 Daiichi Sankyo Company Information
  57. 7.10.2 Daiichi Sankyo Business Overview
  58. 7.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
  60. 7.10.5 Daiichi Sankyo Recent Developments
  61. 7.11 Prestige
  62. 7.11.1 Prestige Company Information
  63. 7.11.2 Prestige Business Overview
  64. 7.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Prestige Opioid-Induced Constipation Product Portfolio
  66. 7.11.5 Prestige Recent Developments
  67. 7.12 GSK
  68. 7.12.1 GSK Company Information
  69. 7.12.2 GSK Business Overview
  70. 7.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 GSK Opioid-Induced Constipation Product Portfolio
  72. 7.12.5 GSK Recent Developments
  73. 7.13 Shionogi
  74. 7.13.1 Shionogi Company Information
  75. 7.13.2 Shionogi Business Overview
  76. 7.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
  78. 7.13.5 Shionogi Recent Developments
8 North America
  1. 8.1 North America Opioid-Induced Constipation Market Size by Type
  2. 8.1.1 North America Opioid-Induced Constipation Revenue by Type (2021-2032)
  3. 8.1.2 North America Opioid-Induced Constipation Sales by Type (2021-2032)
  4. 8.1.3 North America Opioid-Induced Constipation Price by Type (2021-2032)
  5. 8.2 North America Opioid-Induced Constipation Market Size by Application
  6. 8.2.1 North America Opioid-Induced Constipation Revenue by Application (2021-2032)
  7. 8.2.2 North America Opioid-Induced Constipation Sales by Application (2021-2032)
  8. 8.2.3 North America Opioid-Induced Constipation Price by Application (2021-2032)
  9. 8.3 North America Opioid-Induced Constipation Market Size by Country
  10. 8.3.1 North America Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Opioid-Induced Constipation Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Opioid-Induced Constipation Market Size by Type
  2. 9.1.1 Europe Opioid-Induced Constipation Revenue by Type (2021-2032)
  3. 9.1.2 Europe Opioid-Induced Constipation Sales by Type (2021-2032)
  4. 9.1.3 Europe Opioid-Induced Constipation Price by Type (2021-2032)
  5. 9.2 Europe Opioid-Induced Constipation Market Size by Application
  6. 9.2.1 Europe Opioid-Induced Constipation Revenue by Application (2021-2032)
  7. 9.2.2 Europe Opioid-Induced Constipation Sales by Application (2021-2032)
  8. 9.2.3 Europe Opioid-Induced Constipation Price by Application (2021-2032)
  9. 9.3 Europe Opioid-Induced Constipation Market Size by Country
  10. 9.3.1 Europe Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Opioid-Induced Constipation Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Opioid-Induced Constipation Market Size by Type
  2. 10.1.1 China Opioid-Induced Constipation Revenue by Type (2021-2032)
  3. 10.1.2 China Opioid-Induced Constipation Sales by Type (2021-2032)
  4. 10.1.3 China Opioid-Induced Constipation Price by Type (2021-2032)
  5. 10.2 China Opioid-Induced Constipation Market Size by Application
  6. 10.2.1 China Opioid-Induced Constipation Revenue by Application (2021-2032)
  7. 10.2.2 China Opioid-Induced Constipation Sales by Application (2021-2032)
  8. 10.2.3 China Opioid-Induced Constipation Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Opioid-Induced Constipation Market Size by Type
  2. 11.1.1 Asia Opioid-Induced Constipation Revenue by Type (2021-2032)
  3. 11.1.2 Asia Opioid-Induced Constipation Sales by Type (2021-2032)
  4. 11.1.3 Asia Opioid-Induced Constipation Price by Type (2021-2032)
  5. 11.2 Asia Opioid-Induced Constipation Market Size by Application
  6. 11.2.1 Asia Opioid-Induced Constipation Revenue by Application (2021-2032)
  7. 11.2.2 Asia Opioid-Induced Constipation Sales by Application (2021-2032)
  8. 11.2.3 Asia Opioid-Induced Constipation Price by Application (2021-2032)
  9. 11.3 Asia Opioid-Induced Constipation Market Size by Country
  10. 11.3.1 Asia Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Opioid-Induced Constipation Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Opioid-Induced Constipation Market Size by Type
  2. 12.1.1 SAMEA Opioid-Induced Constipation Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Opioid-Induced Constipation Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Opioid-Induced Constipation Price by Type (2021-2032)
  5. 12.2 SAMEA Opioid-Induced Constipation Market Size by Application
  6. 12.2.1 SAMEA Opioid-Induced Constipation Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Opioid-Induced Constipation Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Opioid-Induced Constipation Price by Application (2021-2032)
  9. 12.3 SAMEA Opioid-Induced Constipation Market Size by Country
  10. 12.3.1 SAMEA Opioid-Induced Constipation Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Opioid-Induced Constipation Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Opioid-Induced Constipation Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Opioid-Induced Constipation Value Chain Analysis
  2. 13.1.1 Opioid-Induced Constipation Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Opioid-Induced Constipation Production Mode & Process
  6. 13.2 Opioid-Induced Constipation Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Opioid-Induced Constipation Distributors
  9. 13.2.3 Opioid-Induced Constipation Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst